Ken Griffin Biovie Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$0.4 - $0.56 $13,800 - $19,320	-34,500 Reduced 66.73%	17,200 $6,000
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $24,963 - $89,019	-47,100 Reduced 47.67%	51,700 $27,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $5.24 $89,182 - $383,044	73,100 Added 284.44%	98,800 $124,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $5.17 $2,475 - $4,653	900 Added 3.63%	25,700 $87,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $59,305 - $120,204	14,500 Added 140.78%	24,800 $106,000
Q1 2023 May 15, 2023	BUY	$4.89 - $10.53 $50,367 - $108,459	10,300 New	10,300 $83,000

4.73M

17.2K

27K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $83.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.